<産業資料/調査レポートの題名> 2022年6月19日

無針ドラッグデリバリーデバイスの世界市場:製品別、地域別


◆英文タイトル:Needle-free Drug Delivery Devices Market by Product and Geography - Forecast and Analysis 2020-2024

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Value chain analysis
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
• Market outlook
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Inhalers – Market size and forecast 2019-2024
• Transdermal patches – Market size and forecast 2019-2024
• Jet injectors – Market size and forecast 2019-2024
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Technological advances in needle-free drug delivery devices
• Research and funding for development of needle-free drug delivery devices
• Increasing government initiatives
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• 3M Co.
• Antares Pharma Inc.
• Becton, Dickinson and Co.
• Enesi Pharma Ltd.
• GlaxoSmithKline Plc
• Inovio Pharmaceuticals Inc.
• Mylan NV
• Novartis AG
• PharmaJet Inc.
• Valeritas Holdings Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global healthcare equipment market
Exhibit 02: Segments of global healthcare equipment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendors: Key offerings
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Product – Market share 2019-2024 (%)
Exhibit 19: Comparison by product
Exhibit 20: Inhalers – Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Rate of hospital admissions for asthma and COPD (number of people per 100,000 population)
Exhibit 22: Inhalers – Year-over-year growth 2020-2024 (%)
Exhibit 23: Transdermal patches – Market size and forecast 2019-2024 ($ millions)
Exhibit 24: Transdermal patches – Year-over-year growth 2020-2024 (%)
Exhibit 25: Jet injectors – Market size and forecast 2019-2024 ($ millions)
Exhibit 26: Jet injectors – Year-over-year growth 2020-2024 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2019-2024 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 32: North America – Year-over-year growth 2020-2024 (%)
Exhibit 33: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 35: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 37: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Estimated cases of children with type 1 diabetes 2017 (per 100,000 children)
Exhibit 42: Product launch
Exhibit 43: Strategic alliances
Exhibit 44: Product recalls
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: M Co. – Vendor overview
Exhibit 52: M Co. – Business segments
Exhibit 53: M Co. – Organizational developments
Exhibit 54: M Co. – Geographic focus
Exhibit 55: M Co. – Segment focus
Exhibit 56: M Co. – Key offerings
Exhibit 57: M Co. – Key customers
Exhibit 58: Antares Pharma Inc. – Vendor overview
Exhibit 59: Antares Pharma Inc. – Business segments
Exhibit 60: Antares Pharma Inc. – Organizational developments
Exhibit 61: Antares Pharma Inc. – Geographic focus
Exhibit 62: Antares Pharma Inc. – Key offerings
Exhibit 63: Antares Pharma Inc. – Key customers
Exhibit 64: Becton, Dickinson and Co. – Vendor overview
Exhibit 65: Becton, Dickinson and Co. – Business segments
Exhibit 66: Becton, Dickinson and Co. – Organizational developments
Exhibit 67: Becton, Dickinson and Co. – Geographic focus
Exhibit 68: Becton, Dickinson and Co. – Segment focus
Exhibit 69: Becton, Dickinson and Co. – Key offerings
Exhibit 70: Becton, Dickinson and Co. – Key customers
Exhibit 71: Enesi Pharma Ltd. – Vendor overview
Exhibit 72: Enesi Pharma Ltd. – Business segments
Exhibit 73: Enesi Pharma Ltd. – Organizational developments
Exhibit 74: Enesi Pharma Ltd. – Key offerings
Exhibit 75: Enesi Pharma Ltd. – Key customers
Exhibit 76: GlaxoSmithKline Plc – Vendor overview
Exhibit 77: GlaxoSmithKline Plc – Business segments
Exhibit 78: GlaxoSmithKline Plc – Organizational developments
Exhibit 79: GlaxoSmithKline Plc – Geographic focus
Exhibit 80: GlaxoSmithKline Plc – Segment focus
Exhibit 81: GlaxoSmithKline Plc – Key offerings
Exhibit 82: GlaxoSmithKline Plc – Key customers
Exhibit 83: Inovio Pharmaceuticals Inc. – Vendor overview
Exhibit 84: Inovio Pharmaceuticals Inc. – Business segments
Exhibit 85: Inovio Pharmaceuticals Inc. – Organizational developments
Exhibit 86: Inovio Pharmaceuticals Inc. – Key offerings
Exhibit 87: Inovio Pharmaceuticals Inc. – Key customers
Exhibit 88: Mylan NV – Vendor overview
Exhibit 89: Mylan NV – Product segments
Exhibit 90: Mylan NV – Organizational developments
Exhibit 91: Mylan NV – Geographic focus
Exhibit 92: Mylan NV – Segment focus
Exhibit 93: Mylan NV – Key offerings
Exhibit 94: Mylan NV – Key customers
Exhibit 95: Novartis AG – Vendor overview
Exhibit 96: Novartis AG – Business segments
Exhibit 97: Novartis AG – Organizational developments
Exhibit 98: Novartis AG – Geographic focus
Exhibit 99: Novartis AG – Segment focus
Exhibit 100: Novartis AG – Key offerings
Exhibit 101: Novartis AG – Key customers
Exhibit 102: PharmaJet Inc. – Vendor overview
Exhibit 103: PharmaJet Inc. – Business segments
Exhibit 104: PharmaJet Inc. – Organizational developments
Exhibit 105: PharmaJet Inc. – Key offerings
Exhibit 106: PharmaJet Inc. – Key customers
Exhibit 107: Valeritas Holdings Inc. – Vendor overview
Exhibit 108: Valeritas Holdings Inc. – Business segments
Exhibit 109: Valeritas Holdings Inc. – Organizational developments
Exhibit 110: Valeritas Holdings Inc. – Key offerings
Exhibit 111: Valeritas Holdings Inc. – Key customers
Exhibit 112: Validation techniques employed for market sizing
Exhibit 113: Definition of market positioning of vendors


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark